WO1999001450A1 - POLYMORPHS OF 8-CHLORO-6, 11-DIHYDRO-11- (4-PIPERIDYLIDENE) -5H-BENZO[5,6] CYCLOHEPTA[1,2-b]PYRIDINE - Google Patents
POLYMORPHS OF 8-CHLORO-6, 11-DIHYDRO-11- (4-PIPERIDYLIDENE) -5H-BENZO[5,6] CYCLOHEPTA[1,2-b]PYRIDINE Download PDFInfo
- Publication number
- WO1999001450A1 WO1999001450A1 PCT/US1998/013433 US9813433W WO9901450A1 WO 1999001450 A1 WO1999001450 A1 WO 1999001450A1 US 9813433 W US9813433 W US 9813433W WO 9901450 A1 WO9901450 A1 WO 9901450A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymorph form
- descarbonylethoxyloratadine
- crystalline polymorph
- approximately
- characteristic peaks
- Prior art date
Links
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 241000124008 Mammalia Species 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 5
- 239000002480 mineral oil Substances 0.000 claims description 17
- 235000010446 mineral oil Nutrition 0.000 claims description 17
- 238000002329 infrared spectrum Methods 0.000 claims description 15
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 13
- 230000003266 anti-allergic effect Effects 0.000 claims description 8
- 229960003088 loratadine Drugs 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 5
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 description 24
- 239000007787 solid Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 15
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 15
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000002798 spectrophotometry method Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001387 anti-histamine Effects 0.000 description 4
- -1 e.g. Substances 0.000 description 4
- 238000011194 good manufacturing practice Methods 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
- 229960005286 carbaryl Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to crystalline polymorphs of 8-chloro- 6 / ll-dihydro-ll-(4-piperidylidene)-5H-benzo[5 / 6]cyclohepta[l / 2-b]pyridine (hereinafter "descarbonylethoxyloratadine”) represented by the formula
- compositions containing such polymorphs and methods of using such polymorphs to treat allergic reactions in mammals.
- U.S. Patent No. 4,659,716 discloses descarbonylethoxyloratadine which possesses antihistaminic properties with substantially no sedative properties. This U.S. Patent also discloses methods of making descarbonylethoxyloratadine and using it to treat allergic reactions in mammals.
- descarbonylethoxyloratadine can exist in the form of two distinct crystalline polymorphs, each having distinctly different physical properties.
- this invention provides crystalline polymorph form 1 descarbonylethoxyloratadine essentially free of polymorph form 2 and characterized by the following x-ray powder diffraction pattern having characteristic peaks expressed in terms of "d" spacing and relative intensities("RI") at approximately:
- This invention further provides crystalline polymorph form 2 descarbonylethoxyloratadine substantially free of poymorph form 1 and characterized by the following x-ray powder diffraction pattern having characteristic peaks expressed in terms of "d" spacing and relative intensities("RI") approximately: . spacing ( ⁇ 0.04) El 8.34 Weak 6.87 Medium 6.20 Medium 4.90 Medium
- Figure 1 presents the infrared spectrum of crystalline polymorph form 1 descarbonylethoxyloratadine as a mull in mineral oil.
- Figure 2 presents an infrared spectrum of crystalline polymorph form 2 descarbonylethoxyloratadine as a mull in mineral oil.
- polymorph form 1 essentially free of polymorph form 2 means that descarbonylethoxyloratadine polymorph form 1 prepared in accordance with this invention contains less than about 1% of form 2 as measured by infrared spectral analysis on a FTIR spectrometer.
- the polymorph form 1 prepared in accordance with Examples 1 and 2 had no detectable amount of form 2 by FTIR spectrophotometry.
- polymorph form 2 substantially free of polymorph form 1 means that the descarbonylethoxyloratadine polymorph form 2 prepared in accordance with this invention contains less than about 15%, preferably less than about 10%, and more preferably less than about 5-8% of form 1 as measured by infrared spectral analysis on a FTIR spectrometer.
- Descarboxyloratine prepared as described in U.S. Patent No. 4,659,716 was isolated as the acetic acid salt (Example III) and as a mixture of polymorphs of the free base from hexane (see Examples V + VI).
- descarbonylethoxyloratadine exists as a mixture of polymorphs. Such a mixture could lead to production of a descarbonylethoxyloratadine product which would exist as a variable mixture of variable composition (i.e., variable percent amounts of polymorphs) having variable physical properties, a situation unacceptable in view of stringent GMP requirements.
- variable mixture of variable composition i.e., variable percent amounts of polymorphs
- Ether solvents such as dioxane produced form 1 substantially free of form 2 but other alkane ethers, e.g., di- isopropyl ether produced form 1 with significant amounts of form 2 and din-butyl ether favored formation of form 2.
- Ketones such as methyl isobutyl ketone produced crystalline polymorph form 1 essentially free of form 2 but methyl butyl ketone produced a 8:1 ratio of form 1 to form 2.
- Use of methyl isubutyl ketone is preferred to produce crystalline polymorph form 1 essentially free of form 2.
- a more complete infrared spectrum of crystalline polymorph form 2 descarbonylethoxyloratadine taken as a mull in mineral oil is characterized by the following characteristic peaks( in reciprocal centimeters at approximately:
- the x-ray powder diffraction patterns were measured on a Philips APD3720 automated diffractometer system (model PW 1800).
- the radiation source was copper (K-alpha) and the long fine focus tube connected to a Philips XRG 3100 x-ray generator operated at 45 KV and 40 mA.
- the take-off angle was 6 degrees and a graphite monochromator as used.
- a scintillation detector was employed and data was acquired with a scan rate of 0.025 degrees per second, a step size of 0.010 and a step time of 40 seconds per degree.
- a more complete x-ray powder diffraction pattern for crystalline polymorph form 1 descarbonylethoxyloratadine having characteristic peaks expressed in terms of "d" spacing and relative intensities("RI”) is provided hereinbelow:
- the x-ray powder diffraction pattern distinctive for crystalline polymorph form 2 having characteristic peaks expressed in terms of "d" spacing and relative intensities("RI”) is provided hereinbelow:
- compositions of this invention may contain in addition to an anti-allergically effective amount of crystalline polymorph form 1 or form 2 descarbonylethoxyloratadine as the active ingredient, inert pharmaceutically acceptable carriers that may be solids or liquids.
- Solid form compositions include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
- a solid carrier can be one or more substances which may also act as diluants, flavoring agents, solubilizers, lubricants, suspending agents, binders or tablet disintegration agents; it can also be an encapsulating material.
- the carrier is a finely divided solid which is in admixture with the finely divided active compound.
- the active compound is mixed with carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain from about 5 to about 20 percent of the active ingredient.
- Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methycelluloseose, sodium carboxy methyl- cellulose, a low melting wax. cocoa butter and the like.
- compositions is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component (with or without other carriers) is surrounded by carrier, which is thus in association with it. Similarly, caches are included. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
- a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
- Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for topical administration. Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution.
- Aqueous solutions suitable for oral use can be prepared by adding the active component in water and adding suitable colorants, flavors, stabilizing, sweetening, solubilizing and thickening agents as desired.
- Aqueous suspensions suitable for oral use can e made by dispersing the finely divided active component in water with viscous material, i.e., natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose and other well-known suspending agents.
- Topical formulation useful for nasal or ophthalmic administration are also contemplated.
- Topical formulation suitable for nasal administration may be solutions or suspensions.
- Ophthalmic formulations may be solutions, suspension or ointments.
- Ointments usually contain lipophilic carriers such as mineral oil and /or petrolatum.
- Solution for ophthalmic administration may contain sodium chloride, acid and/or base to adjust the pH as well as purified water and preservatives.
- the anti-allergic effective amount of polymorph form 1 or form 2 descarbonylethoxyloratadine for topical administration varies from 0.1 to 5% by weight of the total pharmaceutical composition.
- the preferred amount varies from 0.5 to 2% by weight of the total pharmaceutical composition.
- the anti-allergic effective amount of polymorph form 1 or form 2 descarbonylethoxyloratadine for oral administration varies from about 1 to 50 mg/day, preferably about 2.5 to 20 mg/day and more preferably about 5 to 10 mg/day in single or divided doses. The most preferred amount is 5.0 mg, once a day.
- the precise dosage and dosage regimen may be varied depending upon the requirements of the patients, (e.g.. his or her sex, age) as well as the severity of the allergic condition being treated. Determination of the proper dosage and dosage regimen for a particular patient will be within the skill of the attending clinician.
- Loratadine( 45 Kg, 117 moles) was refluxed in about 180 liters of ethanol containing potassium hydroxide (about 40.5 Kg, excess) for about 5 hours to complete the carbomate hydrolysis( see also Example VI of U.S. Patent No. 4,659,716).
- the warm reaction mixture was diluted with about 135 liters of water and distilled at atmospheric pressure until a reaction mixture temperature of 105-110°C was achieved.
- the reaction mixture was than cooled to 50-70°C, diluted with about 135 liters of methyl isobutyl ketone (MIBK), and the so-formed mixture was reheated to 80-90°C to redissolve solids.
- the aqueous layer was separated, and the MIBK layer was washed with additional portions of water until a pH of 6-9 was achieved in the aqueous layer.
- MIBK methyl isobutyl ketone
- the MIBK layer was then concentrated under atmospheric pressure and slowly cooled to -5 to 0°C as crude descarbonylethoxyloratadine crystallized. Crude descarbonylethoxyloratadine was filtered, washed with MIBK, and dried at about 60°C to produce about 33.5 Kg (92% of theory) of crude descarbonyl-ethoxy loratadine which may also be carried into the next step as a wet cake.
- Crystalline polymorph form 1 was micronized using a fluid energy mill and packaged in double polyethylene bags in a fiber drum closed with a metal ring.
- thermocouple and nitrogen gas source was added
- thermocouple and nitrogen gas source was added lOg of descarbonylethoxyloratadine (prepared as described in Example VI of USP 4,65,716) and 150 mL of di-n-butyl ether. The so- formed mixture was heated to 100 °C and held at this temperature until all solid material dissolved, and a clear solution was formed.
- second 250 mL three neck round bottom flask("second flask) equipped identically as the first flask was added 50mL of di-n-butyl ether. The second flask was cooled to -50 °C.
- a cendula was connected to both flasks and the ends of the cendula were placed below the surface of the solutions in both flasks. Nitrogen pressure was applied to the first flask sufficient to completely force the solution in first flask into the second flask. The temperature of the second flask was maintained at below -20 °C and the so-formed very turbid solution in the second flask was stirred for five minutes. The resulting precipitate was vaccum filtered. The solid was dried in a vaccum oven under a nitrogen atmosphere at room temperature. No heat was applied to prevent discoloration of the product. Seven grams (7 g) of polymorph form 2 descarbonylethoxyloratadine was obtained as a crystalline solid which contained 92% ( ⁇ 5%) of form 2 by FTIR spectrophotometry.
- Samples of crystalline polymorph form 1 prepared in accordance with this invention were subjected to stability testing at various temperatures (25, 30 and 40 °C) and relative humidities of 60%, 60% and 75%, respectively.
- Assay for form 1 and total related compounds were performed including physical appearance, X-ray diffraction, FTIR (identity), FTIR (polymorph ratio) and pH. No significant change ( ⁇ 1%) from initial sample % form 1 and related compounds was observed.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA2000010519A UA62976C2 (en) | 1997-07-02 | 1998-01-07 | Polymorphs of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine |
IL13338798A IL133387A (en) | 1997-07-02 | 1998-07-01 | POLYMORPHS OF 8-CHLORO-6-,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5-H-BENZO [5,6] CYCLOHEPTA [1,2b] PYRIDINE |
SK1852-99A SK185299A3 (en) | 1997-07-02 | 1998-07-01 | Polymorphs of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h- benzo[5,6] cyclohepta[1,2-b]pyridine |
BR9811658-4A BR9811658A (en) | 1997-07-02 | 1998-07-01 | Polymorphs of 8-chloro-6,11-dihydro-11- (4-piperidylidene) -5h-benzo [5,6] -cyclohepta [1,2-b] pyridine |
DE69814076T DE69814076T2 (en) | 1997-07-02 | 1998-07-01 | SHAPE 8-CHLORINE-6,11-DIHYDRO-11- (4-PIPERIDYLIDENE) -5H-BENZO [5,6] CYCLOHEPTA [1,2.B] PYRIDINE POLYMORPH |
NZ501417A NZ501417A (en) | 1997-07-02 | 1998-07-01 | Crystalline polymorphs of descarbonylethoxyloratadine (8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6] cyclohepta[1,2-b]pyridine) and methods for their use |
HU0004308A HUP0004308A3 (en) | 1997-07-02 | 1998-07-01 | Polymorphs of 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine |
AU82710/98A AU734487B2 (en) | 1997-07-02 | 1998-07-01 | Polymorphs of 8-chloro-6, 11-dihydro-11- (4-piperidylidene) -5H-benzo(5,6) cyclohepta(1,2-b)pyridine |
AT98932930T ATE239010T1 (en) | 1997-07-02 | 1998-07-01 | 8-CHLORINE-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO(5,6)CYCLOHEPTA(1,2.B)PYRIDINE POLYMORPHOUS FORMS |
CA002294352A CA2294352C (en) | 1997-07-02 | 1998-07-01 | Polymorphs of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6] cyclohepta[1,2-b]pyridine |
EP98932930A EP0993455B1 (en) | 1997-07-02 | 1998-07-01 | POLYMORPHS OF 8-CHLORO-6, 11-DIHYDRO-11- (4-PIPERIDYLIDENE) -5H-BENZO[5,6] CYCLOHEPTA[1,2-b]PYRIDINE |
JP50726599A JP2002507991A (en) | 1997-07-02 | 1998-07-01 | Polymorphs of 8-chloro-6,11-dihydro-11- (4-piperidylidene) -5H-benzo [5,6] cyclohepta [1,2-b] pyridine |
NO996547A NO996547L (en) | 1997-07-02 | 1999-12-29 | Polymorphs of 8-chloro-6,11-dihydro-11- (4-piperidylidene) -5H-benzo [5,6] cyclohepta [1,2-b] pyridine |
HK00102387A HK1024687A1 (en) | 1997-07-02 | 2000-04-20 | Polymorphs of 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6] cyclohepta[1,2-b]pyridine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88676697A | 1997-07-02 | 1997-07-02 | |
US08/886,766 | 1997-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999001450A1 true WO1999001450A1 (en) | 1999-01-14 |
Family
ID=25389724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/013433 WO1999001450A1 (en) | 1997-07-02 | 1998-07-01 | POLYMORPHS OF 8-CHLORO-6, 11-DIHYDRO-11- (4-PIPERIDYLIDENE) -5H-BENZO[5,6] CYCLOHEPTA[1,2-b]PYRIDINE |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP0993455B1 (en) |
JP (2) | JP2002507991A (en) |
KR (1) | KR20010014316A (en) |
CN (1) | CN1261886A (en) |
AR (1) | AR013161A1 (en) |
AT (1) | ATE239010T1 (en) |
AU (1) | AU734487B2 (en) |
BR (1) | BR9811658A (en) |
CA (1) | CA2294352C (en) |
CO (1) | CO4940423A1 (en) |
DE (1) | DE69814076T2 (en) |
ES (1) | ES2197480T3 (en) |
HK (1) | HK1024687A1 (en) |
HU (1) | HUP0004308A3 (en) |
IL (1) | IL133387A (en) |
MY (1) | MY132943A (en) |
NO (1) | NO996547L (en) |
NZ (1) | NZ501417A (en) |
PE (1) | PE86399A1 (en) |
PL (1) | PL337712A1 (en) |
RU (1) | RU2197485C2 (en) |
SK (1) | SK185299A3 (en) |
TR (1) | TR199903308T2 (en) |
UA (1) | UA62976C2 (en) |
WO (1) | WO1999001450A1 (en) |
ZA (1) | ZA985783B (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1251852A1 (en) | 2000-02-03 | 2002-10-30 | Schering Corporation | Use of desloratadine for treating allergic and inflammatory conditions |
WO2003086275A2 (en) * | 2002-04-15 | 2003-10-23 | Sun Pharmaceutical Industries Limited | Preperation of desloratatine |
WO2004012738A1 (en) * | 2002-08-05 | 2004-02-12 | Sandoz Ag | Novel salt and polymorphs of desloratadine hemifumarate |
WO2004080461A2 (en) * | 2003-03-12 | 2004-09-23 | TEVA Gyógyszergyár Részvénytársaság | Stable pharmaceutical compositions of desloratadine |
WO2006003479A2 (en) * | 2004-07-07 | 2006-01-12 | EGIS Gyógyszergyár Rt. | New pseudopolymorph of desloratadine formed with carbon dioxide |
WO2008050162A1 (en) * | 2006-10-26 | 2008-05-02 | EGIS GYÓGYSZERGYÁR Nyilvånosan Müködö Részvénytársaság | Process for the preparation of desloratadine adduct formed with carbon dioxide |
WO2008056202A2 (en) * | 2005-11-17 | 2008-05-15 | Teva Pharmaceutical Industries Ltd. | Desloratadine crystalline forms mixtures having a low level of residual solvents |
WO2008062253A2 (en) * | 2005-11-17 | 2008-05-29 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine |
WO2008138563A1 (en) * | 2007-05-11 | 2008-11-20 | Ratiopharm Gmbh | Pharmaceutical composition comprising desloratadine |
EP2269586A1 (en) | 2009-07-01 | 2011-01-05 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical composition comprising desloratadine |
WO2011141483A2 (en) | 2010-05-10 | 2011-11-17 | Laboratorios Lesvi, S.L. | Stable pharmaceutical formulations containing an antihistaminic |
EP2727592A1 (en) | 2012-11-05 | 2014-05-07 | Kücükgüzel, Sükriye Güniz | A combination of desloratadine and paracetamol |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103755682A (en) * | 2013-12-30 | 2014-04-30 | 山东达因海洋生物制药股份有限公司 | Novel crystal form for desloratadine and preparation method thereof |
CN108358892A (en) * | 2018-04-11 | 2018-08-03 | 常州方圆制药有限公司 | A kind of method of purification of Desloratadine crude product |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0152897A1 (en) * | 1984-02-15 | 1985-08-28 | Schering Corporation | 8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta-[1,2-b]pyridine and its salts, processes for the production thereof and pharmaceutical compositions containing these compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3677842D1 (en) * | 1985-05-13 | 1991-04-11 | Schering Corp | METHOD FOR THE PRODUCTION OF PIPERIDYLIDES-DIHYDRODIBENZO (A, D) CYCLOHEPTENES AND THEIR AZODERIVATES, COMPOUNDS MADE THEREOF AND THEIR USE FOR THE PREPARATION OF MEDICINAL PRODUCTS. |
-
1998
- 1998-01-07 UA UA2000010519A patent/UA62976C2/en unknown
- 1998-07-01 AR ARP980103203A patent/AR013161A1/en unknown
- 1998-07-01 AT AT98932930T patent/ATE239010T1/en not_active IP Right Cessation
- 1998-07-01 CO CO98037139A patent/CO4940423A1/en unknown
- 1998-07-01 ZA ZA985783A patent/ZA985783B/en unknown
- 1998-07-01 DE DE69814076T patent/DE69814076T2/en not_active Expired - Lifetime
- 1998-07-01 TR TR1999/03308T patent/TR199903308T2/en unknown
- 1998-07-01 IL IL13338798A patent/IL133387A/en not_active IP Right Cessation
- 1998-07-01 JP JP50726599A patent/JP2002507991A/en active Pending
- 1998-07-01 HU HU0004308A patent/HUP0004308A3/en unknown
- 1998-07-01 KR KR1019997012456A patent/KR20010014316A/en not_active Application Discontinuation
- 1998-07-01 AU AU82710/98A patent/AU734487B2/en not_active Ceased
- 1998-07-01 CN CN98806712A patent/CN1261886A/en active Pending
- 1998-07-01 NZ NZ501417A patent/NZ501417A/en unknown
- 1998-07-01 CA CA002294352A patent/CA2294352C/en not_active Expired - Fee Related
- 1998-07-01 PL PL98337712A patent/PL337712A1/en unknown
- 1998-07-01 ES ES98932930T patent/ES2197480T3/en not_active Expired - Lifetime
- 1998-07-01 EP EP98932930A patent/EP0993455B1/en not_active Expired - Lifetime
- 1998-07-01 BR BR9811658-4A patent/BR9811658A/en not_active IP Right Cessation
- 1998-07-01 RU RU2000102669/04A patent/RU2197485C2/en not_active IP Right Cessation
- 1998-07-01 SK SK1852-99A patent/SK185299A3/en unknown
- 1998-07-01 WO PCT/US1998/013433 patent/WO1999001450A1/en not_active Application Discontinuation
- 1998-07-02 MY MYPI98003024A patent/MY132943A/en unknown
- 1998-07-02 PE PE1998000594A patent/PE86399A1/en not_active Application Discontinuation
-
1999
- 1999-12-29 NO NO996547A patent/NO996547L/en not_active Application Discontinuation
-
2000
- 2000-04-20 HK HK00102387A patent/HK1024687A1/en not_active IP Right Cessation
-
2009
- 2009-07-27 JP JP2009174701A patent/JP2009242436A/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0152897A1 (en) * | 1984-02-15 | 1985-08-28 | Schering Corporation | 8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta-[1,2-b]pyridine and its salts, processes for the production thereof and pharmaceutical compositions containing these compounds |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1251852A1 (en) | 2000-02-03 | 2002-10-30 | Schering Corporation | Use of desloratadine for treating allergic and inflammatory conditions |
WO2003086275A2 (en) * | 2002-04-15 | 2003-10-23 | Sun Pharmaceutical Industries Limited | Preperation of desloratatine |
WO2003086275A3 (en) * | 2002-04-15 | 2004-02-12 | Sun Pharmaceutical Ind Ltd | Preperation of desloratatine |
US7678908B2 (en) * | 2002-04-15 | 2010-03-16 | Sun Pharmaceutical Industries Limited | Process of preparing desaloratadine |
WO2004012738A1 (en) * | 2002-08-05 | 2004-02-12 | Sandoz Ag | Novel salt and polymorphs of desloratadine hemifumarate |
US6962924B2 (en) | 2002-08-05 | 2005-11-08 | Sandoz Ag | Salt and polymorphs of desloratadine hemifumarate |
WO2004080461A2 (en) * | 2003-03-12 | 2004-09-23 | TEVA Gyógyszergyár Részvénytársaság | Stable pharmaceutical compositions of desloratadine |
WO2004080461A3 (en) * | 2003-03-12 | 2004-10-28 | Biogal Gyogyszergyar | Stable pharmaceutical compositions of desloratadine |
EA011894B1 (en) * | 2004-07-07 | 2009-06-30 | Эгиш Дьёдьсердьяр Нирт. | New pseudopolymorph of desloratadine formed with carbon dioxide |
WO2006003479A3 (en) * | 2004-07-07 | 2006-06-08 | Egyt Gyogyszervegyeszeti Gyar | New pseudopolymorph of desloratadine formed with carbon dioxide |
WO2006003479A2 (en) * | 2004-07-07 | 2006-01-12 | EGIS Gyógyszergyár Rt. | New pseudopolymorph of desloratadine formed with carbon dioxide |
WO2008056202A2 (en) * | 2005-11-17 | 2008-05-15 | Teva Pharmaceutical Industries Ltd. | Desloratadine crystalline forms mixtures having a low level of residual solvents |
WO2008062253A2 (en) * | 2005-11-17 | 2008-05-29 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine |
WO2008056202A3 (en) * | 2005-11-17 | 2008-08-28 | Teva Pharma | Desloratadine crystalline forms mixtures having a low level of residual solvents |
WO2008062253A3 (en) * | 2005-11-17 | 2008-09-04 | Teva Pharma | Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine |
WO2008050162A1 (en) * | 2006-10-26 | 2008-05-02 | EGIS GYÓGYSZERGYÁR Nyilvånosan Müködö Részvénytársaság | Process for the preparation of desloratadine adduct formed with carbon dioxide |
WO2008138563A1 (en) * | 2007-05-11 | 2008-11-20 | Ratiopharm Gmbh | Pharmaceutical composition comprising desloratadine |
EP2269586A1 (en) | 2009-07-01 | 2011-01-05 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical composition comprising desloratadine |
WO2011000518A1 (en) | 2009-07-01 | 2011-01-06 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmaceutical composition comprising desloratadine |
WO2011141483A2 (en) | 2010-05-10 | 2011-11-17 | Laboratorios Lesvi, S.L. | Stable pharmaceutical formulations containing an antihistaminic |
EP2727592A1 (en) | 2012-11-05 | 2014-05-07 | Kücükgüzel, Sükriye Güniz | A combination of desloratadine and paracetamol |
Also Published As
Publication number | Publication date |
---|---|
EP0993455A1 (en) | 2000-04-19 |
KR20010014316A (en) | 2001-02-26 |
BR9811658A (en) | 2000-09-05 |
DE69814076D1 (en) | 2003-06-05 |
EP0993455B1 (en) | 2003-05-02 |
CO4940423A1 (en) | 2000-07-24 |
JP2002507991A (en) | 2002-03-12 |
SK185299A3 (en) | 2000-07-11 |
CA2294352A1 (en) | 1999-01-14 |
NZ501417A (en) | 2000-10-27 |
AR013161A1 (en) | 2000-12-13 |
PE86399A1 (en) | 1999-10-23 |
NO996547D0 (en) | 1999-12-29 |
ES2197480T3 (en) | 2004-01-01 |
HUP0004308A2 (en) | 2001-10-28 |
TR199903308T2 (en) | 2000-11-21 |
UA62976C2 (en) | 2004-01-15 |
AU8271098A (en) | 1999-01-25 |
CA2294352C (en) | 2008-05-06 |
JP2009242436A (en) | 2009-10-22 |
IL133387A0 (en) | 2001-04-30 |
HUP0004308A3 (en) | 2004-07-28 |
DE69814076T2 (en) | 2004-02-26 |
NO996547L (en) | 2000-03-01 |
ZA985783B (en) | 1999-01-19 |
CN1261886A (en) | 2000-08-02 |
ATE239010T1 (en) | 2003-05-15 |
RU2197485C2 (en) | 2003-01-27 |
IL133387A (en) | 2004-02-08 |
HK1024687A1 (en) | 2000-10-20 |
AU734487B2 (en) | 2001-06-14 |
MY132943A (en) | 2007-10-31 |
PL337712A1 (en) | 2000-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6506767B1 (en) | 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine | |
JP2009242436A (en) | POLYMORPHIC FORM OF 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]-PYRIDINE | |
CA2305803C (en) | Crystalline antifungal polymorph | |
JP2002501529A (en) | Novel form of S-omeprazole | |
ZA200500372B (en) | Novel salt and polymorphs of desloratadine hemifumarate | |
KR20150046369A (en) | Polymorphic forms of deferasirox (icl670a) | |
JPH05506249A (en) | Bisbenzocycloheptapiperidylidene, piperidine and piperazine compounds, compositions and uses | |
CA2464961A1 (en) | Polymorphous forms of rosiglitazone maleate | |
CA2615842A1 (en) | Polymorphs of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine | |
KR100446099B1 (en) | (2-morpholinylmethyl) benzamide derivative | |
MXPA00000133A (en) | POLYMORPHS OF 8-CHLORO-6, 11-DIHYDRO-11- (4-PIPERIDYLIDENE) -5H-BENZO[5,6]CYCLOHEPTA[1, 2-b]PYRIDINE | |
JPH02290855A (en) | Benzazepine derivative | |
CZ460399A3 (en) | Polymorphs of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo/5,6/cyclohepta/1,2¡b/pyridine | |
EP0864572B1 (en) | Crystal of hydrate and process for preparation thereof | |
WO1999019322A1 (en) | ETHYL 4-(8-CHLORO-5, 6-DIHYDRO-11H- BENZO[5,6]CYCLOHEPTA [1,2-b]PYRIDIN -11-YLIDENE)-1- PIPERIDENE CARBOXYLATE POLYMORPH | |
JPH0561275B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 133387 Country of ref document: IL Ref document number: 98806712.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GE GW HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 501417 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 82710/98 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2294352 Country of ref document: CA Ref document number: 2294352 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-4603 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 185299 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998932930 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997012456 Country of ref document: KR Ref document number: 1999/03308 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/000133 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 1998932930 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-4603 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997012456 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 82710/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998932930 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1999-4603 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997012456 Country of ref document: KR |